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On the prevention of secondary hyperparathyroidism in experi-
mental chronic renal disease. Secondary hyperparathyroidism in
chronic renal disease appears to begin with the first phase of
nephron destruction and to progress in severity with advancing
nephron loss. If phosphorus (P) intake remains constant during
the evolution of chronic renal disease, each time that glomerular
filtration rate (GFR) decreases, a transient period of P reten-
tion will follow. The ionized calcium concentration presumably
will fall under these circumstances and the latter will stimulate
the parathyroid glands. To prevent the development of second-
ary hyperparathyroidism, studies were performed in a group of
seven dogs in which P intake was decreased in the diet propor-
tionally to the decrease in GFR. P intake initially was 1200 mg/
24 hrs and gradually was decreased to a mean of 234± 15.7 mg/
24 hrs. In control studies mean GFR was 56 mI/mm and tubular
reabsorption of phosphorus (TRP), 95%. As GFR was decreased
progressively to a mean of 12 mI/mm, TRP remained at 92%.
Parathyroid hormone (PTH) levels averaged 43 4.6 tl equi-
valnts per ml in the control phase and 45 4.6 jil Eq/ml in the
final phase of the study. These data provide support for the view
that the adaptation in P excretion imposed by a constant P in-
take and a decreasing nephron population plays an important
role in the pathogenesis of secondary hyperparathyroidism.
Moreover, they suggest that if the necessity for the adaptation
is obviated, hyperparathyroidism may be prevented, at least
until the onset of vitamin D resistance.
Prevention du hyperparathyroidisme secondaire de Ia maladie
du rein chronique et experimentale. L'hyperparathyroidisme
secondaire de la maladie chronique du rein semble commencer
au premiere stade de Ia destruction des néphrons, et devenir
plus en plus sévCre au fur et a mesure de la perte ds néphrons.
Si l'apport de phosphore (P) demeure constant pendant l'evolu-
tion de Ia maladie chronique du rein, chacque fois que le debit
de filtration-glomérulaire (DGF) diminue, il s'ensuit une période
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éphemère de retention de P. Dans ce cas on peut s'attendre que
Ia concentration de calcium ionisé diminue, ce qui doit stimuler
les glandes parathyroides. Pour prévenir le développement de
l'hyperparathyroidisme, on a étudié un groupe de sept chiens
chez lesquels l'apport alimentaire de P a été proportionellement
a Ia diminution du DFG. L'apport de P était a l'origine de
1200 mg/24 hrs et a gradullement été diminué pour atteindre
une moyenne de 234 16 mg/24 hrs. La moyenne du DFG chez
des experiences contrôles était de 56 mI/mm et Ia reabsorption
tubulaire de phosphore (RTP) de 95%. Tandis que le DFG
diminuait progressivement pour atteindre une moyenne de
12 mI/mm, Ia RTP demeurait 92%. Les niveaux de l'hormone
parathyroide (HPT) était en moyenne 43 4.6 equivalents per
ml pendant la période contrôle, et 45 4.6 tl Eq/mi au stade
finale de l'experience. D'après ces données ii est permis de
penser que l'adaptation de l'excrétion de P imposée par un
apport constant de P et un nombre décroissant de néphrons joue
un role important dans Ia pathogenCse del'hyperparathyroidisme
sécondaire. Ii semble en outre que si Ia nécessité d'une adaptation
eSt eliminée, l'hyperparathyroidisme se trouve prévenu, tout au
moms jusqu au commencement de Ia resistance a Ia vitamineD.
Secondary hyperparathyroidism is a difficult and often
serious complication of long-standing chronic renal disease.
In addition to the skeletal manifestations, metastatic
calcification, peripheral vascular calcification, and severe
pruritis have been attributed to the increased parathyroid
hormone (PTH) levels in the blood [1—10].
We recently have suggested [11] that secondary hyper-
parathyroidism in advancing renal disease may occur, to a
major degree, as an expression of the adaptation of the
biologic control system governing the maintenance of
external phosphorus (P) balance. The hypothesis is based
upon the assumption that each time a permanent fall in
GFR occurs in chronic renal disease, the absolute rate of
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phosphorus excretion must fall transiently; if phosphorus
intake remains constant, there must follow a period of
phosphorus retention in body fluids until the rate of
phosphorus excretion by the residual nephrons is re-
adjusted upwards. According to the hypothesis, the adapta-
tion in phosphorus excretion occurs through the following
mechanisms. With the transient rise in serum phosphorus,
a reciprocal fall in ionized calcium of the blood occurs, and
the latter leads to an increase in parathyroid hormone
secretion. The increased activity of PTH in the blood
reaching the renal tubules increases the level of inhibition
of net phosphorus reabsorption and thus increases phos-
phorus excretion per residual nephron. External phosphorus
balance, thereby, is restored until the next period of nephron
destruction.
To examine the validity of the foregoing hypothesis,
studies recently were performed on dogs subjected to
sequential reduction of renal mass [12]. Two groups of
animals were studied: in one group, phosphorus intake was
maintained constant at 1200 mg per day; in the other,
phosphorus intake was maintained constant at less than
100 mg per day. The first group manifested the expected
fall in fractional phosphorus reabsorption as GFR dimin-
ished; moreover, PTH levels rose progressively reaching
strikingly high concentrations at the lowest levels of GFR
obtained. In the second group, however, fractional phos-
phorus reabsorption did not decrease progressively, i.e.,
progressive phosphaturia per nephron was not observed;
and of critical importance, PTH levels remained normal
even in the presence of uremia [12].
While these results supported the initial hypothesis,
interpretations are restricted by the extreme limitations of
phosphorus intake on the low phosphorus diet; phosphorus
depletion might have mobilized calcium from the skeleton,
influencing the release of PTH. To obviate this problem,
a protocol involving "proportional reduction" of phos-
phorus was designed and employed in the present studies
in a group of dogs subjected to serial and sequential reduc-
tion of renal mass.
If the pathogenesis of secondary hyperparathyroidism
relates to a continuing increase in the ratio of the quantity
of phosphorus requiring excretion to the number of nephrons
available to accomplish the excretion, then the adaptation
in phosphorus excretion should be preventable. Thus, if
phosphorus intake were to be decreased in proportion to
the decrement in GFR, the requirements for phosphorus
excretion per residual nephrons (or more accurately, per
unit of GFR) should remain constant as GFR falls. Second-
ary hyperparathyroidism thus should be prevented, at least
until vitamin D resistance develops. In addition to eliminat-
ing the risk of phosphorus depletion, "proportional
reduction" of phosphorus has another important con-
notation; the regimen should lend itself to clinical applica-
tion without imposing major interference with the quality
of a patient's life.
Methods
Studies were performed in a group of seven healthy
adult female mongrel dogs. The animals were fed a low
phosphorus (less than 100 mg/ 300 g) synthetic diet (Nutri-
tional Biochemical Corp., Cleveland, Ohio) which was
composed of 20% protein, 70% carbohydrate, and 10% fat.
150 grams of this diet were administered by gastric tube
twice daily providing a total caloric intake of 1200 calories.
Phosphorus was added to the diet (as potassium phos-
phate 1) according to the schedule bescri bed below. Calcium
intake was maintained constant throughout the study at
1250 50 mg per day.
Studies were performed at four levels of renal function
(Fig. 1). For the initial studies, both kidneys were intact.
Thereafter the renal mass of the right kidney was diminished
by approximately 70% by ligating terminal branches of the
right renal artery. After an appropriate interval of time
(generally from seven to 10 days), studies were repeated
and the left kidney was subjected to 70% infarction. After
recovery from this procedure and the performance of the
third set of studies, the left kidney was removed entirely
leaving the animal only with the residual nephrons of the
right kidney. The final set of experiments was then per-
formed.
The initial level of phosphorus intake was 1200 mg per
day and was maintained for at least 10 days. After the
first surgical procedure, the phosphorus intake was
diminished in proportion to the estimated reduction in
total renal mass and the new intake was maintained until
the next set of clearance studies was performed seven to
10 days later. In general, the estimated reduction in GFR
based on the fraction of renal mass infarcted proved quite
accurate; however, if there was an error of greater than
10%, the phosphorus intake was readjusted, an additional
period of at least five days was allowed and the studies
were repeated. The same procedure was followed after
the second and third periods of nephron destruction.
The animals were trained and the clearance studies were
performed without the use of anesthesia. GFR was measured
as the exogenous creatinine clearance and phosphate clear-
ance was measured concurrently. Four or more 15 to
45 mm clearance periods were obtained during each study.
Urine was collected through a permanent single cystostomy
tube. Blood samples were drawn through an indwelling
jugular venous catheter which was maintained in place
during the clearance studies only. Parathyroid hormone
levels were measured during the control phase (i.e., before
any reduction of renal mass with the dogs on a 1200 mg
daily phosphorus intake) and again during the final period
of study after renal function and phosphorus had been
reduced maximally. Creatinine was determined according
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Fig. 2. The effects of proportional reduction in phosphate intake
in a representative dog with experimental decrease in GFR.
Fig. 1. Diagram of the experimental model for the development
of progressive experimental renal disease in the dog.
to the method of Bosnes and Taussky [13], phosphate
according to the method of Gomori [14], and calcium and
magnesium were measured using an atomic absorption
spectrophotometer (IL Model 153). Serum PTH was deter-
mined by a modification of the radioimmunoassay techni-
que of Berson, Yalow, Aurbach and Potts [15] as modified
by Reiss and Canterbury [12, 16].
Results
Fig. 2 depicts the results obtained in a representative
dog in which phosphorus intake was decreased in propor-
tion to the decrement in GFR. Glomerular filtration rate
was reduced in steps from an initial value of 53 mI/mm to
a final value of 14 mi/mm over a period of six weeks.
Phosphorus intake was decreased from the initial level
of 1200 mg per day to a final level of 250 mg per day.
Throughout the study, the ratio of phosphorus intake to
GFR remained constant. No change was observed in the
concentration of either serum phosphorus or calcium.
Moreover, there was no decrease in the fraction of filtered
phosphorus reabsorbed with values remaining above 90%
even in the presence of advanced renal failure. Finally, the
concentration of serum PTH was 57 units before the onset
of nephron reduction and 59 units after maximal nephron
reduction. This value for PTH is in striking contrast to the
average value of over 1000 units in dogs subjected to the
same pattern of nephron reduction, but maintained on
1200 mg of phosphorus daily throughout [12].
Table 1 presents mean results obtained in all seven dogs.
The control value for GFR averaged 56 mi/mm and the
subsequent values were 40, 19, and 12 mI/mm. Phosphorus
intake was 1200 mg/day in the control period and was
decreased in proportion to the decrement in GFR in the
succeeding phases of study. Plasma phosphorus concentra-
tion averaged 4.2 mg/100 ml initially; subsequent values
were 4.0, 4.2, and 3.8 mg/100 ml. None of the latter three
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1 40 800 4.0 9.7 1.82 95
2 19 400 4.2 9.7 1.56 90
3 12 234 3.8 10.2 2.18 45 92
SE ±1.1 ±15.7 ±0.36 ±0,30 ±0.40 ±4.6 ±3.8
F <0.001 <0.001 NS NS NS NS NS
All the results represent the mean values for four or more clearance periods.
Abbreviations: GFR, glomerular filtration rate; Pa,, plasma phosphorus; RCa' plasma calcium; Mg' plasma magnesium; PTH, para-
thyroid hormone levels in microliter equivalents per ml of serum; TRP, tubular reabsorption of phosphorus.
values differs significantly from the control value. Plasma
calcium concentration also remained normal throughout,
and there was no significant difference between the final
value and the control value. Plasma magnesium concentra-
tions also were measured in these animals and the data are
included in Table 1. No significant increase in magnesium
occurred. Fractional phosphorus reabsorption remained
above 90% throughout, and again the final value was not
significantly different from the control value. Finally PTH
concentration averaged 43 jil equivalents per ml in the
control phase and 45 p1 equivalents per ml in the final
phase of study.
Discussion
If the entrance of phosphorus into the extracellular
fluid remains relatively constant as the number of nephrons
decreases in chronic renal disease, the only way in which
external balance of P can be maintained is to increase P
excretion per residual nephron. This adaptation in excretion
occurs with good precision and, on a normal phosphorus
intake, hyperphosphatemia generally does not occur until
GFR is reduced by as much as 75% [17]. The adaptation
in P excretion is associated with a progressive rise in plasma
parathyroid hormone levels [12] and presumably the latter
are responsible in major degree for the increased P excre-
tion per nephron [18].
To prevent the adaptation in P excretion would require
that the amount of P requiring excretion decrease in pro-
portion to the fall in GFR. In the present study, a regimen
of "proportional reduction" of phosphorus was employed
in a group of dogs subjected to sequential reduction of
renal nass. The data confirm the view that if phosphorus
is reduced in proportion to the decrement in glomerular
filtration rate, fractional excretion of phosphorus in the
residual nephrons will not increase and secondary hyper-
parathyroidism will not occur. We believe that these
observations obtained in the dogs subjected to proportional
reduction of phosphorus intake could have clinical implica-
tions. Were phosphorus intake to be decreased in patients
with advancing renal disease relatively early in their course
and in the absence of either overt evidence of hyperpara-
thyroidism or hyperphosphatemia, it is possible that
secondary hyperparathyroidism could be delayed or
prevented. The reduction in phosphorus absorption could
be produced either by decreasing the phosphorus content
of the diet or by decreasing the net enteric absorption of
phosphorus using phosphate-binding gels or resins. At
whatever point in the natural history of advancing renal
disease vitamin D resistance affected the absorption of
calcium in the gastrointestinal tract, a tendency towards
hypocalcemia would tend to promote an increase in the
secretory rate of parathyroid hormone independent of the
phosphorus intake. However, this element in the syndrome
of uremic osteodystrophy may be preventable by the use
of vitamin D or one of the more active metabolites [19].
Finally, if hydrogen ion retention is ultimately shown to
contribute significantly to uremic osteodystrophy, the
judicious administration of sodium bicarbonate or other
proton acceptors (probably in quantities of less than 20 to
30 mEq/day) should obviate this abnormality also.
In summary, we believe that secondary hyperparathyroid-
ism occurs in major degree as a "trade-off" [20] for the
adaptation in phosphorus excretion required to maintain
external phosphorus balance in advancing renal disease.
However, if the adaptation can be prevented, the untoward
consequences should also be prevented. When phosphorus
intake was decreased in exact proportion to the decrement
in renal mass and GFR, no adaptation in phosphorus
excretion occurred and no increase in parathyroid levels
was observed. If other of the abnormalities of the uremic
state occur in consequence of adaptations in the excretion
of other solutes, the concept of "proportional reduction"
of solutes may have implications that extend beyond the
prevention of secondary hyperparathyroidism.
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